secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cartesian Therapeutics, Inc. (RNAC)
CIK:        0001453687
Form:       8-K
Filed at:   2023-01-09T23:59:59+00:00
Accession:  0001453687-23-000037
Event type: m_and_a
Sentiment:  positive
Materiality: 0.70
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Selecta licenses Xork IgG protease to Astellas for up to $340M plus royalties for Pompe disease
--------------------------------------------------------------------------------

- Licenses Xork to Astellas for $10M upfront, up to $340M in milestones plus royalties on sales for Pompe disease.
- Phase 3 DISSOLVE I & II topline data for SEL-212 in chronic refractory gout expected in Q1 2023.
- Selected IL-2 development candidate to combine with ImmTOR for autoimmune diseases; IND-enabling studies planned in 2023.
- Initiated Phase 1/2 ReiMMAgine trial of SEL-302 (AAV gene therapy + ImmTOR) for methylmalonic acidemia.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1453687/000145368723000037/0001453687-23-000037-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1453687/000145368723000037/selb-20230104.htm
  HTML page:      https://secwatch.observer/filing/0001453687-23-000037

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer